查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1947332

全球原料藥配製市場（依製劑類型、最終用戶、給藥途徑、應用及分銷通路分類）預測（2026-2032年）

Bulk-Drug Compounding Market by Compounding Type, End User, Route Administration, Application, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025 年，大宗藥品配製市場價值為 68.7 億美元，預計到 2026 年將成長至 71.9 億美元，年複合成長率為 5.31%，到 2032 年將達到 98.8 億美元。

關鍵市場統計數據
基準年 2025 68.7億美元
預計年份：2026年 71.9億美元
預測年份 2032 98.8億美元
複合年成長率 (%) 5.31%

本文清楚概述了客製化藥物配製如何在臨床個體化、嚴格的品管和不斷變化的供應鏈預期之間取得平衡。

大宗藥品配製產業處於臨床需求與供應鏈複雜性的交匯點，透過定製配方和精確給藥途徑，滿足了患者獨特的用藥需求，而這些需求是現成產品無法滿足的。配製實驗室和專科藥房將臨床處方箋轉化為針對各種適應症的個人化治療方案，提供用於急性護理的無菌注射劑、用於皮膚科的非無菌外用製劑以及用於視力保健的精細眼科製劑。隨著臨床需求的不斷變化，人們對活性藥物成分和輔料的監管合規性、品質保證和可追溯來源的期望也在不斷提高。

自動化、數位化追溯和醫療服務分散化如何重塑整個產業的藥房實踐、分銷模式和品質預期

在技​​術日趨成熟、監管日益嚴格以及醫療服務模式不斷變革的推動下，藥房生態系統正經歷著一場變革浪潮。隨著自動化和封閉式配藥設備的應用，常規無菌配藥流程正從人工批量處理轉向經過檢驗、可重複的工作流程，從而降低污染風險和操作差異。同時，數位化追溯解決方案和電子批記錄提高了藥品生命週期各個階段的透明度，使得在出現偏差時能夠更快地進行根本原因分析，並簡化監管檢查流程。

分析關稅政策變化如何加劇採購風險、增加營運複雜性並加速策略性回流和供應商多元化決策。

關稅政策會對藥局營運產生連鎖反應，影響投入成本、供應商選擇和庫存策略。當藥品原料、成品和包裝材料的關稅增加時，藥局通常會採取一些措施，例如分散採購來源、認證二級供應商以及提高安全存量基準，以降低價格波動和供應中斷的風險。雖然這些措施有助於提高醫療服務的連續性，但也增加了營運資金需求和營運複雜性，尤其對於缺乏大規模採購系統的小規模獨立藥房而言更是如此。

深入的細分洞察揭示了製劑類型、終端用戶環境、給藥途徑、臨床應用和分銷管道如何決定營運和商業優先事項。

細分市場有助於理解治療需求與生產複雜性和分銷需求之間的觀點。依製劑類型分析，非無菌製劑和無菌製劑都需要不同的品質系統和設施佈局。無菌製劑需要無塵室環境、檢驗的無菌操作規程和無菌檢測，而非無菌製劑的生產則更側重於產品穩定性、患者接受度以及外用和口服產品的精確劑量。從終端用戶的觀點來看，醫療機構和專科診所優先考慮產品的便攜性、便捷給藥方式和較長的保存期限，而醫院藥房則需要高通量的無菌注射劑和嚴格的批次追溯，以滿足住院患者的需求。

影響籌資策略、分銷選擇和區域分銷優先事項的關鍵全球市場的區域趨勢和監管細微差別

區域趨勢對美洲、歐洲、中東和非洲以及亞太地區的供應鏈設計、監管要求和臨床實踐模式有著深遠的影響。在美洲，整合式醫療保健系統和成熟的專科藥房網路強調集中採購和報銷機制的協調，而法律規範制定了嚴格的配藥標準，並影響設施投資和驗證方法。在歐洲、中東和非洲地區，不同的法規結構和跨境貿易協定造成了複雜的合規路徑。在某些地區，集中化的藥典標準促進了協調統一，而在其他地區，當地法規要求則需要量身定做的品管和標籤方法。

藥局服務競爭分析：技術卓越、供應鏈深度與顧客親密度如何創造永續優勢

從專科藥局和合約配藥商到經銷商和通路合作夥伴，各大產業參與者在經銷商鏈上佔據不同的位置，他們負責將藥品供應到醫療點。大型配藥機構憑藉持續的合規性、經認證的無塵室運作以及良好的測試記錄脫穎而出。他們通常會投資自動化、電子批記錄和穩定性測試能力，以降低變異性並加快批次放行決策。同時，小規模的業者往往透過專注於特定治療領域、提供個人化的患者服務以及靈活的交付方式來滿足緊急的臨床需求，從而獲得競爭優勢。

藥局領導者可以採取哪些切實可行的步驟來加強供應鏈、改善品質系統並重新構想其分散式醫療服務的商業性模式

產業領導者應採取果斷行動，加強供應鏈韌性，加快品質現代化進程，並調整商業模式以適應不斷變化的醫療服務模式。首先，擴大供應商合格計劃，並投資關鍵活性成分和包裝材料的雙重籌資策略，將降低單點故障和政策主導的成本飆升的風險。其次，優先採用檢驗的自動化和電子品質管理系統，將減少批次間差異，並有助於加快合規速度。這將使無菌生產規模得以擴大，而無需成比例地增加人工操作風險。

採用嚴謹的混合方法研究框架，結合訪談、實地觀察、監管審查和細分主導分析，以確保研究結果具有可操作性和可複製性。

支撐這些發現的研究結合了定性和定量方法，以確保分析的穩健性和多方面性。主要資料來源包括對藥房經理、醫院藥屋主任、專科診所採購人員和物流合作夥伴的結構化訪談，並輔以對持證機構的現場觀察。次要資訊來源包括監管指導文件、藥典標準以及關於無菌加工、穩定性測試和給藥途徑要求的技術文獻。研究採用三角驗證技術來檢驗供應商的風險描述，並調和報告的實務與觀察到的工作流程之間的差異。

本文概述了整合採購、品質和商業策略對於維持可靠、以患者為中心的藥房服務至關重要的原因。

藥房行業正處於一個轉折點，品質現代化、供應鏈多元化以及應對分散式醫療服務的應對力將決定藥房的生存。隨著臨床需求日益分散到住院、專科診所和居家醫療等領域，藥房必須在滿足個人化藥物配送需求與確保品質​​穩定和符合監管要求所需的營運規範之間取得平衡。投資於檢驗的自動化系統、供應商合格和分銷完整性已不再是可選項，而是實現臨床可靠性和策略規模的必要基礎。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 依配製類型分類的散裝藥品配製市場

  • 非無菌製劑
  • 無菌製劑

9. 依最終用戶分類的散裝藥品配製市場

  • 家庭醫療保健
  • 醫院藥房
  • 零售藥房
  • 專科診所

10. 依給藥途徑分類的原料藥配製市場

  • 注射
    • 肌肉內注射
    • 靜脈注射
    • 皮下注射
  • 眼藥水
    • 眼藥水
    • 軟膏
  • 口服
    • 膠囊
    • 解決方案
    • 懸浮液
  • 外用藥物
    • 奶油
    • 洗劑
    • 軟膏

第11章 依應用分類的原料藥配製市場

  • 心臟病學
  • 皮膚科
  • 腫瘤學
  • 疼痛管理

第12章 依分銷通路分類的散裝藥品配製市場

  • 線上
  • 離線

13. 各地區原料藥配製市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 依組別分類的原料藥配製市場

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國散裝藥品配製市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

16. 美國原料藥配製市場

17. 中國：原料藥配製市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AmerisourceBergen Corporation
  • Apothecary By Design
  • Athenex, Inc.
  • Avella Specialty Pharmacy
  • B. Braun Melsungen AG
  • Baxter International Inc.
  • Cantrell Drug Company
  • Cardinal Health, Inc.
  • Central Admixture Pharmacy Services, Inc.
  • Fagron NV
  • Foundation Care
  • Fresenius Kabi AG
  • ICU Medical, Inc.
  • ImprimisRx
  • Leiters Health
  • McKesson Corporation
  • Nephron Pharmaceuticals Corporation
  • Olympia Pharmacy
  • Pfizer CentreOne
  • PharMEDium Services, LLC
  • Precision Dose, Inc.
  • QuVa Pharma, Inc.
  • SCA Pharma
  • Vertice Pharma
  • Wedgewood Pharmacy
Product Code: MRR-4F7A6D4FB696

The Bulk-Drug Compounding Market was valued at USD 6.87 billion in 2025 and is projected to grow to USD 7.19 billion in 2026, with a CAGR of 5.31%, reaching USD 9.88 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 6.87 billion
Estimated Year [2026] USD 7.19 billion
Forecast Year [2032] USD 9.88 billion
CAGR (%) 5.31%

An incisive overview of how tailored pharmaceutical compounding reconciles clinical personalization with stringent quality controls and evolving supply chain expectations

The bulk-drug compounding sector sits at the intersection of clinical necessity and supply-chain complexity, where tailored formulations and precise administration routes address patient-specific needs that off-the-shelf products cannot. Compounding laboratories and specialty pharmacies translate clinical prescriptions into individualized therapies across a broad spectrum of indications, delivering sterile injectables for acute care, non-sterile topical agents for dermatology, and delicate ophthalmic preparations for vision care. As clinical demands evolve, so do expectations for regulatory compliance, quality assurance, and traceable sourcing of active pharmaceutical ingredients and excipients.

Moreover, the modern compounding landscape increasingly emphasizes integrated quality systems, data-driven batch control, and validated stability profiles to meet both clinician requirements and payer scrutiny. In practice, this means compounding operations must balance speed-to-patient with robust documentation and risk mitigation, ensuring every formulation conforms to sterility standards, accurately labeled administration routes, and patient-specific contraindication checks. Consequently, stakeholders from formulary managers to procurement teams are re-evaluating supplier relationships and internal capabilities to maintain clinical continuity while improving operational resilience.

How automation, digital traceability, and decentralization of care are reshaping compounding operations, distribution models, and quality expectations across the industry

The compounding ecosystem is undergoing transformative shifts driven by technological maturation, regulatory tightening, and changing care delivery models. Automation and closed-system compounding devices are shifting routine sterile preparation away from manual batch processes toward validated, reproducible workflows that reduce contamination risk and labor variability. At the same time, digital traceability solutions and electronic batch records are increasing transparency across the lifecycle of a compounded product, enabling faster root cause analysis when deviations occur and smoother inspections from regulators.

Concurrently, clinical practice is decentralizing care, with more treatments administered in outpatient specialty clinics and home healthcare settings, raising the bar for stability testing and patient-friendly formulations. These dynamics are reshaping demand profiles for specific administration routes and formulation types, and they are incentivizing investment in cold-chain logistics and ancillary packaging solutions. As a result, compounding operators and their commercial partners are prioritizing partnerships that deliver technological integration, scalable quality systems, and distribution networks capable of supporting diverse end-user environments.

Analyzing how changes in tariff policy can amplify sourcing risks, increase operational complexity, and accelerate strategic reshoring and supplier diversification decisions

Tariff policy can have a cascading effect on compounding operations through its influence on input costs, supplier selection, and inventory strategies. In scenarios where duties on pharmaceutical raw materials, finished goods, or packaging components increase, compounding providers often respond by diversifying supplier bases, qualifying secondary vendors, and increasing safety stock levels to mitigate exposure to price volatility and supply interruptions. These measures improve continuity of care but also elevate working capital requirements and operational complexity, particularly for smaller independent compounding pharmacies that lack extensive procurement infrastructures.

Moreover, tariffs tend to accelerate strategic reshoring and nearshoring conversations, prompting contract manufacturers and distributors to reassess the geographic concentration of critical materials and intermediate processing. When tariff-driven cost pressures coincide with heightened regulatory scrutiny, organizations frequently reprioritize spend toward validated domestic sources and enhanced quality controls, even when unit costs rise. Over time, such reallocations can alter the competitive landscape by favoring companies with scale, integrated supply chains, or existing domestic manufacturing capacity, while also incentivizing collaborative purchasing arrangements and commercial partnerships to spread procurement risk.

In addition, downstream service costs related to storage, customs clearance, and compliance documentation can increase administrative burdens for compounding facilities. To adapt, successful operators emphasize supplier transparency, conduct supplier risk assessments more frequently, and negotiate longer lead times for critical ingredients. As a result, the cumulative impact of tariff shifts is best understood as a structural nudge toward greater supply-chain resilience, diversification of sourcing strategies, and closer alignment between procurement, quality, and clinical teams.

Deep segmentation insight revealing how compounding type, end-user setting, administration route, clinical application, and distribution channel determine operational and commercial priorities

Segmentation provides a useful lens to understand where therapeutic demand converges with manufacturing complexity and distribution needs. When analyzed by compounding type, both non-sterile and sterile preparations demand distinct quality systems and facility layouts; sterile compounding requires clean-room environments, validated aseptic processing, and sterility testing, while non-sterile production focuses on formulation stability, patient acceptability, and accurate dosing for topical and oral products. Looking through the end-user perspective, home healthcare and specialty clinics emphasize portability, simplified administration, and extended shelf-life, whereas hospital pharmacies require high-throughput sterile injectables and rigorous batch traceability to support inpatient demand.

Route-of-administration segmentation clarifies formulation and handling requirements: injectables, including intramuscular, intravenous, and subcutaneous preparations, command the strictest aseptic controls and packaging for safe parenteral use; ophthalmic products, whether drops or ointments, require preservative strategies and particulate control; oral formulations such as capsules, solutions, and suspensions need palatability, stability, and dosing accuracy; and topical forms like creams, lotions, and ointments combine rheology control with skin compatibility testing. Application-based segmentation further differentiates compounding priorities, as cardiology and oncology preparations often demand specialized active ingredients and heightened safety protocols, dermatology products prioritize cosmetic acceptability and local tolerability, and pain-management formulations require both controlled-substance management and patient-specific dose titration. Finally, distribution-channel segmentation-direct sales, online pharmacies, and wholesale distribution-shapes logistical arrangements, regulatory compliance for distribution, and customer engagement models, with each channel presenting distinct trade-offs between reach, control, and margin dynamics. Collectively, these segmentation dimensions create a multidimensional map that informs investment priorities, quality program design, and commercial go-to-market strategies.

Regional dynamics and regulatory nuances across major global markets that drive sourcing strategies, distribution choices, and localized compounding priorities

Regional dynamics exert a profound influence on supply-chain design, regulatory expectations, and clinical practice patterns across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, integrated healthcare systems and established specialty pharmacy networks emphasize consolidation of procurement and a focus on reimbursement alignment, while regulatory oversight enforces stringent compounding standards that shape facility investments and validation practices. Transitioning to Europe, Middle East & Africa, heterogeneous regulatory frameworks and cross-border trade arrangements create a mosaic of compliance pathways; in some jurisdictions, centralized pharmacopoeial standards accelerate harmonization, whereas in others local requirements necessitate bespoke quality and labeling approaches.

In the Asia-Pacific region, a mix of rapid capacity expansion and varied regulatory maturity affects sourcing strategies, with emerging manufacturing hubs offering cost advantages alongside the need for rigorous supplier qualification. Across regions, logistical considerations such as cold-chain infrastructure, customs processes, and distribution density influence decisions about centralized versus localized inventory. Moreover, regional clinical preferences and payer systems play a role in which therapeutic applications or administration routes gain prominence, and these patterns, in turn, inform where compounding investment and partnership models prove most effective. Ultimately, astute companies consider regional nuances holistically-aligning quality systems, supplier portfolios, and distribution models to local requirements while maintaining global standards where feasible.

Competitive landscape analysis highlighting how technical excellence, supply-chain depth, and customer intimacy create durable advantages in compounding services

Key industry players occupy different positions along the value chain, from specialized compounding pharmacies and contract compounding manufacturers to distributors and channel partners that facilitate point-of-care delivery. Leading compounding organizations differentiate by demonstrating consistent regulatory compliance, certified clean-room operations, and an established track record of successful inspections. They often invest in automation, electronic batch records, and stability testing capabilities to reduce variability and accelerate lot-release decisions. Conversely, smaller operators frequently compete through niche therapeutic expertise, personalized patient services, and flexible turnaround times that meet urgent clinical needs.

Across distribution and service partners, companies that provide integrated cold-chain logistics, validated packaging solutions, and regulatory support services gain strategic advantage, particularly for sensitive injectables and biologic-adjacent formulations. Similarly, contract partners that can qualify multiple raw-material sources and maintain rapid analytical capacity for identity and potency testing help compounding providers manage supplier risk. Competitive differentiation also arises from commercial relationships: firms that align closely with hospital systems, specialty clinics, and home health agencies can secure steady demand through embedded formularies and service-level agreements. These patterns illustrate that competitive strength in compounding stems from a combination of technical excellence, supply-chain depth, and customer intimacy.

Actionable steps for compounding leaders to fortify supply chains, modernize quality systems, and realign commercial approaches for decentralized care delivery

Industry leaders should act decisively to strengthen supply-chain resilience, accelerate quality modernization, and align commercial models with shifting care delivery patterns. First, expanding supplier qualification programs and investing in dual-source strategies for critical active ingredients and packaging components will lower vulnerability to single-point failures and policy-driven cost shocks. Second, prioritizing validated automation and electronic quality systems reduces batch variability and supports faster compliance responses, enabling organizations to scale sterile production without proportional jumps in manual labor risk.

Third, commercial teams should remodel go-to-market approaches to reflect the growing importance of outpatient and home-care channels, crafting packaging and administration formats that improve patient adherence and reduce handling complexity. Fourth, organizations ought to deepen partnerships with logistics providers that offer validated cold-chain and track-and-trace capabilities, thereby safeguarding product integrity during distribution. Finally, leaders should embed scenario planning and cross-functional governance into procurement and clinical operations to respond more rapidly to tariff shifts, regulatory updates, or supply disruptions. Collectively, these steps position compounding organizations to meet clinical demand reliably while preserving margin and compliance integrity.

A rigorous mixed-methods research framework combining interviews, facility observation, regulatory review, and segmentation-driven analysis to ensure actionable and reproducible insights

The research underpinning these insights combined qualitative and quantitative techniques to ensure robust, multi-angle analysis. Primary inputs included structured interviews with compounding laboratory managers, hospital pharmacy directors, specialty clinic procurement leads, and logistics partners, complemented by on-site facility observations where permissible. Secondary inputs encompassed regulatory guidance documents, pharmacopoeial standards, and technical literature on aseptic processing, stability testing, and administration-route requirements. Triangulation methods were used to validate supplier risk narratives and to reconcile discrepancies between reported practices and observed workflows.

In addition, the methodology incorporated a segmentation-driven framework to map operational requirements to clinical demand, ensuring that compounding type, end-user setting, administration route, application, and distribution channel considerations were consistently applied across analyses. Sensitivity reviews were performed with subject-matter experts to test assumptions about supply-chain responses to policy changes and to ensure recommendations are practical for both large integrated providers and smaller independent operators. Throughout, transparency in data sources and a commitment to reproducible analytical steps guided the research process.

Concluding synthesis showing why integrating procurement, quality, and commercial strategy is essential to sustain reliable and patient-centered compounding services

The compounding sector faces a pivotal moment in which quality modernization, supply-chain diversification, and responsiveness to decentralized care will determine which organizations thrive. As clinical demand fragments across inpatient, specialty clinic, and home-care settings, compounding providers must reconcile tailored formulation needs with the operational discipline required for consistent quality and regulatory compliance. Investments in validated automation, supplier qualification, and distribution integrity are no longer optional; they are essential enablers of both clinical reliability and strategic scale.

Moving forward, organizations that proactively integrate procurement, quality, and commercial strategy will be best positioned to manage policy-induced cost pressures and supply disruptions while preserving clinical service levels. In short, success in compounding will hinge on the ability to translate segmentation-driven priorities into operational capabilities that support safe, timely, and patient-centered therapies across diverse care settings.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Bulk-Drug Compounding Market, by Compounding Type

  • 8.1. Non Sterile
  • 8.2. Sterile

9. Bulk-Drug Compounding Market, by End User

  • 9.1. Home Healthcare
  • 9.2. Hospital Pharmacies
  • 9.3. Retail Pharmacies
  • 9.4. Specialty Clinics

10. Bulk-Drug Compounding Market, by Route Administration

  • 10.1. Injectables
    • 10.1.1. Intramuscular
    • 10.1.2. Intravenous
    • 10.1.3. Subcutaneous
  • 10.2. Ophthalmic
    • 10.2.1. Drops
    • 10.2.2. Ointment
  • 10.3. Oral
    • 10.3.1. Capsules
    • 10.3.2. Solutions
    • 10.3.3. Suspensions
  • 10.4. Topical
    • 10.4.1. Creams
    • 10.4.2. Lotions
    • 10.4.3. Ointments

11. Bulk-Drug Compounding Market, by Application

  • 11.1. Cardiology
  • 11.2. Dermatology
  • 11.3. Oncology
  • 11.4. Pain Management

12. Bulk-Drug Compounding Market, by Distribution Channel

  • 12.1. Online
  • 12.2. Offline

13. Bulk-Drug Compounding Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Bulk-Drug Compounding Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Bulk-Drug Compounding Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Bulk-Drug Compounding Market

17. China Bulk-Drug Compounding Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. AmerisourceBergen Corporation
  • 18.6. Apothecary By Design
  • 18.7. Athenex, Inc.
  • 18.8. Avella Specialty Pharmacy
  • 18.9. B. Braun Melsungen AG
  • 18.10. Baxter International Inc.
  • 18.11. Cantrell Drug Company
  • 18.12. Cardinal Health, Inc.
  • 18.13. Central Admixture Pharmacy Services, Inc.
  • 18.14. Fagron N.V.
  • 18.15. Foundation Care
  • 18.16. Fresenius Kabi AG
  • 18.17. ICU Medical, Inc.
  • 18.18. ImprimisRx
  • 18.19. Leiters Health
  • 18.20. McKesson Corporation
  • 18.21. Nephron Pharmaceuticals Corporation
  • 18.22. Olympia Pharmacy
  • 18.23. Pfizer CentreOne
  • 18.24. PharMEDium Services, LLC
  • 18.25. Precision Dose, Inc.
  • 18.26. QuVa Pharma, Inc.
  • 18.27. SCA Pharma
  • 18.28. Vertice Pharma
  • 18.29. Wedgewood Pharmacy

LIST OF FIGURES

  • FIGURE 1. GLOBAL BULK-DRUG COMPOUNDING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BULK-DRUG COMPOUNDING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BULK-DRUG COMPOUNDING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BULK-DRUG COMPOUNDING MARKET SIZE, BY COMPOUNDING TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BULK-DRUG COMPOUNDING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BULK-DRUG COMPOUNDING MARKET SIZE, BY ROUTE ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BULK-DRUG COMPOUNDING MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BULK-DRUG COMPOUNDING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BULK-DRUG COMPOUNDING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BULK-DRUG COMPOUNDING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL BULK-DRUG COMPOUNDING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES BULK-DRUG COMPOUNDING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA BULK-DRUG COMPOUNDING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BULK-DRUG COMPOUNDING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BULK-DRUG COMPOUNDING MARKET SIZE, BY COMPOUNDING TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BULK-DRUG COMPOUNDING MARKET SIZE, BY NON STERILE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BULK-DRUG COMPOUNDING MARKET SIZE, BY NON STERILE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BULK-DRUG COMPOUNDING MARKET SIZE, BY NON STERILE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BULK-DRUG COMPOUNDING MARKET SIZE, BY STERILE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BULK-DRUG COMPOUNDING MARKET SIZE, BY STERILE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BULK-DRUG COMPOUNDING MARKET SIZE, BY STERILE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BULK-DRUG COMPOUNDING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BULK-DRUG COMPOUNDING MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BULK-DRUG COMPOUNDING MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BULK-DRUG COMPOUNDING MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BULK-DRUG COMPOUNDING MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BULK-DRUG COMPOUNDING MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BULK-DRUG COMPOUNDING MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BULK-DRUG COMPOUNDING MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BULK-DRUG COMPOUNDING MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BULK-DRUG COMPOUNDING MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BULK-DRUG COMPOUNDING MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BULK-DRUG COMPOUNDING MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BULK-DRUG COMPOUNDING MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BULK-DRUG COMPOUNDING MARKET SIZE, BY ROUTE ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BULK-DRUG COMPOUNDING MARKET SIZE, BY INJECTABLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BULK-DRUG COMPOUNDING MARKET SIZE, BY INJECTABLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BULK-DRUG COMPOUNDING MARKET SIZE, BY INJECTABLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BULK-DRUG COMPOUNDING MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BULK-DRUG COMPOUNDING MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BULK-DRUG COMPOUNDING MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BULK-DRUG COMPOUNDING MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BULK-DRUG COMPOUNDING MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BULK-DRUG COMPOUNDING MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BULK-DRUG COMPOUNDING MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BULK-DRUG COMPOUNDING MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BULK-DRUG COMPOUNDING MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BULK-DRUG COMPOUNDING MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BULK-DRUG COMPOUNDING MARKET SIZE, BY OPHTHALMIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BULK-DRUG COMPOUNDING MARKET SIZE, BY OPHTHALMIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BULK-DRUG COMPOUNDING MARKET SIZE, BY OPHTHALMIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BULK-DRUG COMPOUNDING MARKET SIZE, BY OPHTHALMIC, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BULK-DRUG COMPOUNDING MARKET SIZE, BY DROPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BULK-DRUG COMPOUNDING MARKET SIZE, BY DROPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BULK-DRUG COMPOUNDING MARKET SIZE, BY DROPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BULK-DRUG COMPOUNDING MARKET SIZE, BY OINTMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BULK-DRUG COMPOUNDING MARKET SIZE, BY OINTMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BULK-DRUG COMPOUNDING MARKET SIZE, BY OINTMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BULK-DRUG COMPOUNDING MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BULK-DRUG COMPOUNDING MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BULK-DRUG COMPOUNDING MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BULK-DRUG COMPOUNDING MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BULK-DRUG COMPOUNDING MARKET SIZE, BY CAPSULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BULK-DRUG COMPOUNDING MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BULK-DRUG COMPOUNDING MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BULK-DRUG COMPOUNDING MARKET SIZE, BY SOLUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BULK-DRUG COMPOUNDING MARKET SIZE, BY SOLUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BULK-DRUG COMPOUNDING MARKET SIZE, BY SOLUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BULK-DRUG COMPOUNDING MARKET SIZE, BY SUSPENSIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BULK-DRUG COMPOUNDING MARKET SIZE, BY SUSPENSIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BULK-DRUG COMPOUNDING MARKET SIZE, BY SUSPENSIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BULK-DRUG COMPOUNDING MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BULK-DRUG COMPOUNDING MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BULK-DRUG COMPOUNDING MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BULK-DRUG COMPOUNDING MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BULK-DRUG COMPOUNDING MARKET SIZE, BY CREAMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BULK-DRUG COMPOUNDING MARKET SIZE, BY CREAMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL BULK-DRUG COMPOUNDING MARKET SIZE, BY CREAMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL BULK-DRUG COMPOUNDING MARKET SIZE, BY LOTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL BULK-DRUG COMPOUNDING MARKET SIZE, BY LOTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL BULK-DRUG COMPOUNDING MARKET SIZE, BY LOTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL BULK-DRUG COMPOUNDING MARKET SIZE, BY OINTMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL BULK-DRUG COMPOUNDING MARKET SIZE, BY OINTMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL BULK-DRUG COMPOUNDING MARKET SIZE, BY OINTMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL BULK-DRUG COMPOUNDING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL BULK-DRUG COMPOUNDING MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL BULK-DRUG COMPOUNDING MARKET SIZE, BY CARDIOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL BULK-DRUG COMPOUNDING MARKET SIZE, BY CARDIOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL BULK-DRUG COMPOUNDING MARKET SIZE, BY DERMATOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL BULK-DRUG COMPOUNDING MARKET SIZE, BY DERMATOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL BULK-DRUG COMPOUNDING MARKET SIZE, BY DERMATOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL BULK-DRUG COMPOUNDING MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL BULK-DRUG COMPOUNDING MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL BULK-DRUG COMPOUNDING MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL BULK-DRUG COMPOUNDING MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL BULK-DRUG COMPOUNDING MARKET SIZE, BY PAIN MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL BULK-DRUG COMPOUNDING MARKET SIZE, BY PAIN MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL BULK-DRUG COMPOUNDING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL BULK-DRUG COMPOUNDING MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL BULK-DRUG COMPOUNDING MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL BULK-DRUG COMPOUNDING MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL BULK-DRUG COMPOUNDING MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL BULK-DRUG COMPOUNDING MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL BULK-DRUG COMPOUNDING MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL BULK-DRUG COMPOUNDING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS BULK-DRUG COMPOUNDING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS BULK-DRUG COMPOUNDING MARKET SIZE, BY COMPOUNDING TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS BULK-DRUG COMPOUNDING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS BULK-DRUG COMPOUNDING MARKET SIZE, BY ROUTE ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS BULK-DRUG COMPOUNDING MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 98. AMERICAS BULK-DRUG COMPOUNDING MARKET SIZE, BY OPHTHALMIC, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS BULK-DRUG COMPOUNDING MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS BULK-DRUG COMPOUNDING MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS BULK-DRUG COMPOUNDING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS BULK-DRUG COMPOUNDING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA BULK-DRUG COMPOUNDING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA BULK-DRUG COMPOUNDING MARKET SIZE, BY COMPOUNDING TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA BULK-DRUG COMPOUNDING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA BULK-DRUG COMPOUNDING MARKET SIZE, BY ROUTE ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA BULK-DRUG COMPOUNDING MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA BULK-DRUG COMPOUNDING MARKET SIZE, BY OPHTHALMIC, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA BULK-DRUG COMPOUNDING MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA BULK-DRUG COMPOUNDING MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA BULK-DRUG COMPOUNDING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA BULK-DRUG COMPOUNDING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA BULK-DRUG COMPOUNDING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA BULK-DRUG COMPOUNDING MARKET SIZE, BY COMPOUNDING TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA BULK-DRUG COMPOUNDING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA BULK-DRUG COMPOUNDING MARKET SIZE, BY ROUTE ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA BULK-DRUG COMPOUNDING MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 118. LATIN AMERICA BULK-DRUG COMPOUNDING MARKET SIZE, BY OPHTHALMIC, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA BULK-DRUG COMPOUNDING MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA BULK-DRUG COMPOUNDING MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA BULK-DRUG COMPOUNDING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA BULK-DRUG COMPOUNDING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA BULK-DRUG COMPOUNDING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA BULK-DRUG COMPOUNDING MARKET SIZE, BY COMPOUNDING TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA BULK-DRUG COMPOUNDING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA BULK-DRUG COMPOUNDING MARKET SIZE, BY ROUTE ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA BULK-DRUG COMPOUNDING MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA BULK-DRUG COMPOUNDING MARKET SIZE, BY OPHTHALMIC, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA BULK-DRUG COMPOUNDING MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA BULK-DRUG COMPOUNDING MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA BULK-DRUG COMPOUNDING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA BULK-DRUG COMPOUNDING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE BULK-DRUG COMPOUNDING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE BULK-DRUG COMPOUNDING MARKET SIZE, BY COMPOUNDING TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE BULK-DRUG COMPOUNDING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE BULK-DRUG COMPOUNDING MARKET SIZE, BY ROUTE ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE BULK-DRUG COMPOUNDING MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE BULK-DRUG COMPOUNDING MARKET SIZE, BY OPHTHALMIC, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE BULK-DRUG COMPOUNDING MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE BULK-DRUG COMPOUNDING MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE BULK-DRUG COMPOUNDING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE BULK-DRUG COMPOUNDING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST BULK-DRUG COMPOUNDING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST BULK-DRUG COMPOUNDING MARKET SIZE, BY COMPOUNDING TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST BULK-DRUG COMPOUNDING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST BULK-DRUG COMPOUNDING MARKET SIZE, BY ROUTE ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST BULK-DRUG COMPOUNDING MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 148. MIDDLE EAST BULK-DRUG COMPOUNDING MARKET SIZE, BY OPHTHALMIC, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST BULK-DRUG COMPOUNDING MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST BULK-DRUG COMPOUNDING MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST BULK-DRUG COMPOUNDING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST BULK-DRUG COMPOUNDING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA BULK-DRUG COMPOUNDING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA BULK-DRUG COMPOUNDING MARKET SIZE, BY COMPOUNDING TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA BULK-DRUG COMPOUNDING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA BULK-DRUG COMPOUNDING MARKET SIZE, BY ROUTE ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 157. AFRICA BULK-DRUG COMPOUNDING MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA BULK-DRUG COMPOUNDING MARKET SIZE, BY OPHTHALMIC, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA BULK-DRUG COMPOUNDING MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA BULK-DRUG COMPOUNDING MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 161. AFRICA BULK-DRUG COMPOUNDING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 162. AFRICA BULK-DRUG COMPOUNDING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC BULK-DRUG COMPOUNDING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC BULK-DRUG COMPOUNDING MARKET SIZE, BY COMPOUNDING TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC BULK-DRUG COMPOUNDING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC BULK-DRUG COMPOUNDING MARKET SIZE, BY ROUTE ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 167. ASIA-PACIFIC BULK-DRUG COMPOUNDING MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC BULK-DRUG COMPOUNDING MARKET SIZE, BY OPHTHALMIC, 2018-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC BULK-DRUG COMPOUNDING MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 170. ASIA-PACIFIC BULK-DRUG COMPOUNDING MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 171. ASIA-PACIFIC BULK-DRUG COMPOUNDING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC BULK-DRUG COMPOUNDING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL BULK-DRUG COMPOUNDING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN BULK-DRUG COMPOUNDING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN BULK-DRUG COMPOUNDING MARKET SIZE, BY COMPOUNDING TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN BULK-DRUG COMPOUNDING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN BULK-DRUG COMPOUNDING MARKET SIZE, BY ROUTE ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 178. ASEAN BULK-DRUG COMPOUNDING MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 179. ASEAN BULK-DRUG COMPOUNDING MARKET SIZE, BY OPHTHALMIC, 2018-2032 (USD MILLION)
  • TABLE 180. ASEAN BULK-DRUG COMPOUNDING MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 181. ASEAN BULK-DRUG COMPOUNDING MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 182. ASEAN BULK-DRUG COMPOUNDING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 183. ASEAN BULK-DRUG COMPOUNDING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 184. GCC BULK-DRUG COMPOUNDING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 185. GCC BULK-DRUG COMPOUNDING MARKET SIZE, BY COMPOUNDING TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. GCC BULK-DRUG COMPOUNDING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 187. GCC BULK-DRUG COMPOUNDING MARKET SIZE, BY ROUTE ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 188. GCC BULK-DRUG COMPOUNDING MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 189. GCC BULK-DRUG COMPOUNDING MARKET SIZE, BY OPHTHALMIC, 2018-2032 (USD MILLION)
  • TABLE 190. GCC BULK-DRUG COMPOUNDING MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 191. GCC BULK-DRUG COMPOUNDING MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 192. GCC BULK-DRUG COMPOUNDING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 193. GCC BULK-DRUG COMPOUNDING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION BULK-DRUG COMPOUNDING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPEAN UNION BULK-DRUG COMPOUNDING MARKET SIZE, BY COMPOUNDING TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION BULK-DRUG COMPOUNDING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION BULK-DRUG COMPOUNDING MARKET SIZE, BY ROUTE ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPEAN UNION BULK-DRUG COMPOUNDING MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPEAN UNION BULK-DRUG COMPOUNDING MARKET SIZE, BY OPHTHALMIC, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPEAN UNION BULK-DRUG COMPOUNDING MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPEAN UNION BULK-DRUG COMPOUNDING MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPEAN UNION BULK-DRUG COMPOUNDING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPEAN UNION BULK-DRUG COMPOUNDING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS BULK-DRUG COMPOUNDING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. BRICS BULK-DRUG COMPOUNDING MARKET SIZE, BY COMPOUNDING TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. BRICS BULK-DRUG COMPOUNDING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 207. BRICS BULK-DRUG COMPOUNDING MARKET SIZE, BY ROUTE ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 208. BRICS BULK-DRUG COMPOUNDING MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 209. BRICS BULK-DRUG COMPOUNDING MARKET SIZE, BY OPHTHALMIC, 2018-2032 (USD MILLION)
  • TABLE 210. BRICS BULK-DRUG COMPOUNDING MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 211. BRICS BULK-DRUG COMPOUNDING MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 212. BRICS BULK-DRUG COMPOUNDING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 213. BRICS BULK-DRUG COMPOUNDING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 214. G7 BULK-DRUG COMPOUNDING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 215. G7 BULK-DRUG COMPOUNDING MARKET SIZE, BY COMPOUNDING TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. G7 BULK-DRUG COMPOUNDING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 217. G7 BULK-DRUG COMPOUNDING MARKET SIZE, BY ROUTE ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 218. G7 BULK-DRUG COMPOUNDING MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 219. G7 BULK-DRUG COMPOUNDING MARKET SIZE, BY OPHTHALMIC, 2018-2032 (USD MILLION)
  • TABLE 220. G7 BULK-DRUG COMPOUNDING MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 221. G7 BULK-DRUG COMPOUNDING MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 222. G7 BULK-DRUG COMPOUNDING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 223. G7 BULK-DRUG COMPOUNDING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 224. NATO BULK-DRUG COMPOUNDING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 225. NATO BULK-DRUG COMPOUNDING MARKET SIZE, BY COMPOUNDING TYPE, 2018-2032 (USD MILLION)
  • TABLE 226. NATO BULK-DRUG COMPOUNDING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 227. NATO BULK-DRUG COMPOUNDING MARKET SIZE, BY ROUTE ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 228. NATO BULK-DRUG COMPOUNDING MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 229. NATO BULK-DRUG COMPOUNDING MARKET SIZE, BY OPHTHALMIC, 2018-2032 (USD MILLION)
  • TABLE 230. NATO BULK-DRUG COMPOUNDING MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 231. NATO BULK-DRUG COMPOUNDING MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 232. NATO BULK-DRUG COMPOUNDING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 233. NATO BULK-DRUG COMPOUNDING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 234. GLOBAL BULK-DRUG COMPOUNDING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 235. UNITED STATES BULK-DRUG COMPOUNDING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 236. UNITED STATES BULK-DRUG COMPOUNDING MARKET SIZE, BY COMPOUNDING TYPE, 2018-2032 (USD MILLION)
  • TABLE 237. UNITED STATES BULK-DRUG COMPOUNDING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 238. UNITED STATES BULK-DRUG COMPOUNDING MARKET SIZE, BY ROUTE ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 239. UNITED STATES BULK-DRUG COMPOUNDING MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 240. UNITED STATES BULK-DRUG COMPOUNDING MARKET SIZE, BY OPHTHALMIC, 2018-2032 (USD MILLION)
  • TABLE 241. UNITED STATES BULK-DRUG COMPOUNDING MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 242. UNITED STATES BULK-DRUG COMPOUNDING MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 243. UNITED STATES BULK-DRUG COMPOUNDING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 244. UNITED STATES BULK-DRUG COMPOUNDING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 245. CHINA BULK-DRUG COMPOUNDING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 246. CHINA BULK-DRUG COMPOUNDING MARKET SIZE, BY COMPOUNDING TYPE, 2018-2032 (USD MILLION)
  • TABLE 247. CHINA BULK-DRUG COMPOUNDING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 248. CHINA BULK-DRUG COMPOUNDING MARKET SIZE, BY ROUTE ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 249. CHINA BULK-DRUG COMPOUNDING MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 250. CHINA BULK-DRUG COMPOUNDING MARKET SIZE, BY OPHTHALMIC, 2018-2032 (USD MILLION)
  • TABLE 251. CHINA BULK-DRUG COMPOUNDING MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 252. CHINA BULK-DRUG COMPOUNDING MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 253. CHINA BULK-DRUG COMPOUNDING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 254. CHINA BULK-DRUG COMPOUNDING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)